The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 02, 2025
Filed:
May. 31, 2019
Institut National DE LA Sante ET DE LA Recherche Medicale (Inserm), Paris, FR;
Centre National DE LA Recherche Scientifique, Paris, FR;
Universite D'angers, Angers, FR;
Universite DE Nantes, Nantes, FR;
Assistance Publique—hopitaux DE Paris, Paris, FR;
Sorbonne Universite, Paris, FR;
Frédéric Altare, Nantes, FR;
Guillaume Sarrabayrouse, Barcelona, ES;
Harry Sokol, Paris, FR;
Emmanuelle Godefroy, Nantes, FR;
Francine Jotereau, Nantes, FR;
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), Paris, FR;
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, Paris, FR;
UNIVERSITE D'ANGERS, Angers, FR;
UNIVERSITE DE NANTES, Nantes, FR;
ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, Paris, FR;
SORBONNE UNIVERSITÉ, Paris, FR;
Abstract
The invention relates to a method comprising a step of determining the number, concentration and/or proportion of T lymphocytes with a CD4CD8ααphenotype and further expressing CCR6 and/or CXCR6, for (i) diagnosing, (ii) prognosing outcome of, or (iii) predicting the risk of developing a disease related to a decrease of. The invention also concerns the treatment of said disease by administering a population of these specific T lymphocytes. The Inventors have indeed identified two markers, CCR6 and CXCR6, enabling to select a population of-specific cells among CD4CD8ααT lymphocytes, from a blood sample and without needing to assess theirspecificity. T lymphocytes with a CD4CD8ααCCR6+ CXCR6+ phenotype are for example significantly decreased in IBD patients. The disease related to a decrease ofis particularly an inflammatory bowel disease (IBD), such as Crohn's disease.